Alteon Announces Investor Update Conference Call Thursday, September 9, 2004, 2:00 P.M. Eastern Time
September 01 2004 - 1:46PM
PR Newswire (US)
Alteon Announces Investor Update Conference Call Thursday,
September 9, 2004, 2:00 P.M. Eastern Time - Conference Call to be
Webcast - PARSIPPANY, N.J., Sept. 1 /PRNewswire-FirstCall/ --
Alteon Inc. (AMEX:ALT) announced that it will hold a regularly
scheduled investor update conference call on Thursday, September 9,
2004 at 2:00 p.m. ET. Anyone interested in participating in the
live conference call should RSVP to Nancy Regan at . There will be
a full question and answer period during the call. The call-in
telephone number for the conference call will be 1-800-500-0177.
International participants may call +719-457-2679. Participants
should call approximately 5-10 minutes before 2:00 p.m. In
addition, the conference call will be accessible through a webcast
on the company website, http://www.alteon.com/ in the Investor
Relations section, and a digital rebroadcast will be available
through September 16, 2004 at 11:59 P.M. by dialing 1-888-203-1112,
passcode 896642 for domestic callers and +719-457-0820, passcode
896642 for international callers. About Alteon Alteon is developing
several new classes of drugs that reverse or slow down diseases of
aging and complications of diabetes. These compounds have an impact
on a fundamental pathological process caused by protein-glucose
complexes called Advanced Glycation End-products (A.G.E.s). The
formation and crosslinking of A.G.E.s lead to a loss of flexibility
and function in body tissues, organs and vessels and have been
shown to be a causative factor in many age-related diseases and
diabetic complications. Alteon has created a library of novel
classes of compounds targeting the A.G.E. Pathway. Alteon's lead
compound alagebrium chloride (formerly ALT-711), the only A.G.E.
Crosslink Breaker in advanced human testing, has demonstrated
safety and efficacy in several Phase 2 trials and is actively being
developed for systolic hypertension and heart failure. Ongoing
clinical trials include SPECTRA (Systolic Pressure Efficacy and
Safety Trial of Alagebrium) and PEDESTAL (Patients with Impaired
Ejection Fraction and Diastolic Dysfunction: Efficacy and Safety
Trial of ALagebrium). For more information on Alteon, visit the
company's website at http://www.alteon.com/. Any statements
contained in this press release that relate to future plans, events
or performance are forward-looking statements that involve risks
and uncertainties including, but not limited to, those relating to
technology and product development (including the possibility that
early clinical trial results may not be predictive of results that
will be obtained in large-scale testing or that any clinical trials
will not demonstrate sufficient safety and efficacy to obtain
requisite approvals or will not result in marketable products),
regulatory approval processes, intellectual property rights and
litigation, competitive products, ability to obtain financing, and
other risks identified in Alteon's filings with the Securities and
Exchange Commission. The information contained in this press
release is accurate as of the date indicated. Actual results,
events or performance may differ materially. Alteon undertakes no
obligation to publicly release the result of any revision to these
forward-looking statements that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. DATASOURCE: Alteon Inc. CONTACT: Susan M.
Pietropaolo, Director, Corporate Communications & Investor
Relations of Alteon, +1-201-818-5537 Web site:
http://www.alteon.com/
Copyright
Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jul 2023 to Jul 2024